Physitrack: Steady beginning to 2024 - Redeye

Redeye reiterates its positive stance following Physitrack’s Q1 results. The reported figures met our expectations, with q/q growth returning. The overall outlook is optimistic, and Q2 seems to be off to a solid start. Our view is that the case remains intact, and so is our valuation with a Base case of SEK35, with considerable upside potential in the share price emphasised.

Länk till analysen i sin helhet: https://www.redeye.se/research/1005430/physitrack-steady-beginning-to-2024?utm_source=finwire&utm_medium=RSS